Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 8/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.38 |
| ▸ | BCL2 | P10415 | 3/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14548336 | 0.97 | MCL1 (0.38) | PLA2G4AMCL1BCL2SMPD1TP53 | |
| SCHEMBL14548303 | 0.88 | MCL1 (0.47) | MCL1BCL2PPARGPPARDPPARA | |
| SCHEMBL14548501 | 0.88 | BCL2 (0.42) | MCL1BCL2PPARGPPARDPPARA | |
| SCHEMBL14548338 | 0.87 | BCL2 (0.39) | PLA2G4AMCL1BCL2PPARGPPARD | |
| SCHEMBL14548301 | 0.87 | BCL2 (0.39) | PLA2G4AMCL1BCL2PPARGPPARD | |
| SCHEMBL5659751 | 0.85 | PPARG (0.49) | PLA2G4APPARGPPARDPPARA | |
| SCHEMBL5660741 | 0.82 | PPARG (0.49) | MCL1BCL2PPARGPPARDPPARA | |
| SCHEMBL5660099 | 0.82 | PPARA (0.43) | PLA2G4APPARGPPARDPPARA | |
| SCHEMBL14526736 | 0.81 | RORC (0.41) | PLA2G4AMCL1BCL2SMPD1PPARG | |
| SCHEMBL5658238 | 0.80 | PPARG (0.44) | PLA2G4AMCL1BCL2PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | GPR119, NR1H3, NR1H2 | PLA2G4A 2359/4885MCL1 1367/4885BCL2 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.